Acamprosate: A new tool in the battle against alcohol dependence

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 4, 2006, Pages 445-453

  Wright, Tara M ^a   Myrick, Hugh ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Abstinence; Acamprosate; Alcohol; Alcohol dependence

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; ACETALDEHYDE; ALDEHYDE DEHYDROGENASE; ANTICOAGULANT AGENT; DIAZEPAM; DISULFIRAM; ISONIAZID; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALMEFENE; NALTREXONE; OPIATE; PHENYTOIN; PLACEBO; RIVEA; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ASTHENIA; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DETOXIFICATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FLATULENCE; FLUSHING; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; IMPOTENCE; INSOMNIA; LIVER DYSFUNCTION; LIVER FAILURE; MAINTENANCE THERAPY; META ANALYSIS; NAUSEA; NERVOUSNESS; NEURITIS; OPTIC NEURITIS; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; VOMITING;

EID: 33847264034     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.445     Document Type: Review

References (54)

1. Anonymous. 2005. Acamprosate (Campral) for alcoholism. Med Lett Drugs Ther, 47:1-3.
2. [APA] American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association.
3. Bachteler D, Economidou D, Danysz W, et al. 2005. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology, 30:1104-10.
4. Besson J, Aeby F, Kasas A, et al. 1998. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res, 22:573-9.
5. Boeijinga PH, Parot P, Soufflet L, et al. 2004. Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology, 50:71-7.
6. Boismare F, Daoust M, Moore N, et al. 1984. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav, 21:787-9.
7. Bouza C, Angeles M, Munoz A, et al. 2004. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction, 99:811-28.
8. Chick J, Howlett H, Morgan MY, et al. 2000. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol, 35:176-87.
9. Czachowski CL, Legg BH, Samson HH. 2001. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcohol Clin Exp Res, 25:344-50.
10. Dahchour A, De Witte P. 2000. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol, 60:343-62.
11. De Sousa A, De Sousa A. 2005. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol, 40:545-8.
12. Durbin P, Hulot T, Chabac S. 1995. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In Soyka M (ed). Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral-symposium ESBRA. Stuttgart, Germany: Springer. p 47-64.
13. Forest Pharmaceuticals Inc. 2005. CAMPRAL (acamprosate calcium) delayed-release tablets prescribing information [online]. Accessed 20 June 2006. URL: http://www.campral.com.
14. Garbutt JC, West SL, Carey TS, et al. 1999. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA, 281:1318-25.
15. Gerra G, Caccavari R, Delsignore R, et al. 1992. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Current Therapeutic Research, 52:291-5.
16. Gewiss M, Heidbreder C, Opsomer L, et al. 1991. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol, 26:129-37.
17. Grant BF, Dawson DA, Stinson FS, et al. 2004. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend, 74:223-34.
18. Heyser CJ, Schulteis G, Durbin P, et al. 1998. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology, 18:125-33.
19. Holter SM, Landgraf R, Zieglgansberger W, et al. 1997. Time course of acamprosate action on operant ethanol self-administration alter ethanol deprivation. Alcohol Clin Exp Res, 21:862-8.
20. Johnson BA, Roache JD, Javors MA, et al. 2000. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA, 284:963-71.
21. Kiefer F, Jahn H, Tamaske T, et al. 2003. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry, 60:92-9.
22. Kiefer F, Wiedemann K. 2004. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol, 39:542-7.
23. Knopfel TH, Zeise ML, Cuenod M, et al. 1987. L-homocysteic acid but not L-glutamate is an endogenous N-methyl-D-aspartic acid receptor preferring agonist in rat neocortical neurons in vitro. Neurosci Lett, 81:188-92.
24. Kranzler HR, Van Kirk J. 2001. Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis. Alcohol Clin Exp Res, 25:1335-41.
25. Lesch OM, Walter H. 1996. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol, 31(Suppl 1):63-67.
26. Littleton J. 1995. Acamprosate in alcohol dependence: How does it work? Addiction, 90:1179-88.
27. Littleton J, Zieglgansberger W. 2003. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict, 12(Suppl 1):S3-11.
28. Mallinckrodt. 2005. RiVea (naltrexone hydrochloride) Tablets patient package insert [online]. Accessed on 21 October 2005. URL: http://www.pharmaceuticals.mallinckrodt.com/Products/ Product.asp?ProductID=5406.
29. Mann K, Lehert K, Morgan M. 2004. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res, 28:51-63.
30. Monterosso JR, Flannery BA, Pettinati HM, et al. 2001. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict, 10:258-68.
31. Odyssey Pharmaceuticals, Inc. 2005. Antabuse (disulfiram) Tablets patient package insert [online]. Accessed on 21 October 2005. URL: http://www.odysseypharm.com/productTable.asp?id=16.
32. Olive MF, Nannini MA, Ou CJ, et al. 2002. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol, 437:55-61.
33. Paille FM, Guelfi JD, Perkins AC, et al. 1995. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol, 30:239-47.
34. Palmer AJ, Neeser K, Weiss C, et al. 2000. The long-term cost-effectiveness of improving alcohol abstinence with adjunctive acamprosate. Alcohol Alcohol, 35:478-92.
35. Pelc I, Verbanck P, Le Bon O, et al. 1997. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry, 171:73-7.
36. Poldrugo F, Haeger DA, Comte S, et al. 2005. A critical review of pharmacoeconomic studies of acamprosate. Alcohol Alcohol, 40:422-30.
37. Rivara FP, Garrison MM, Ebel B, et al. 2004. Mortality attributable to harmful drinking in the United States, 2000. J Stud Alcohol, 65:530-6.
38. Rubio G, Jimenez-Arriero MA, Ponce G, et al. 2001. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol, 36:419-25.
39. Rychlik R, Siedentop H, Pfeil T, et al. 2003. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur Addict Res, 9:59-64,
40. Saivin S, Hulot T, Chabac S, et al. 1998. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet, 35:331-45.
41. Sass H, Sokya M, Mann K, et al. 1996. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry, 53:673-80.
42. Scott LJ, Figgitt DP, Kearn SJ et al. 2005. Acamprosate: A review of its use in the maintenance of abstinence in patients with alcohol dependence. CNS Drugs, 19:445-64.
43. Shuckit M, Tapert S. 2004. Alcohol. In Galanter M, Kleber HD (eds) Textbook of substance abuse treatment. 3rd ed. Washington DC: American Psychiatric Publishing, Inc. p 151-166.
44. Sinclair JD. 2001. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol, 36:2-10.
45. Spanagel R, Holter SM, Allingham K, et al. 1996. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol, 305:39-44.
46. Substance Abuse and Mental Health Services Administration. 2002. Results from the 2001 National Household Survey of Drug Abuse: Vol 1. Summary of National Findings. Rockville, MD: Dept of Health and Human Services.
47. Streeton C, Whelan G. 2001. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol, 36:544-52.
48. Ueno S, Harris RA, Messing RO, et al. 2001. Alcohol actions on GABA(A) receptors: from protein structure to mouse behavior. Alcohol Clin Exp Res, 25(Suppl 5):76S-81S.
49. US Department of Health and Human Services. 2000. Tenth Special Report to Congress on Alcohol and Health. Bethesda, MD: US Dept of Health and Human Services.
50. Verheul R, Lehert P, Geerlings PJ, et al. 2005. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl), 178:167-73.
51. Verheul R, van den Brink W, Geerlings P. 1999. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol, 34:197-222.
52. Walker RD, Howard MO, Lambert MD, et al. 1994. Psychiatric and medical comorbidities of veterans with substance use disorders. Hosp Community Psychiatry, 45:232-7
53. Whitworth AB, Fischer F, Lesch OM, et al. 1996. Comparison of acamprosate and placebo and long-term treatment of alcohol dependence. Lancet, 347:1438-42
54. Wilde MI, Wagstaff AJ. 1997. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs, 53:1038-53